Harry Raftopoulos, MD
Dr. Harry Raftopoulos is Vice President and Head of Late-Stage Oncology Clinical Development at Bayer Pharmaceuticals. He joined Bayer in 2017 initially leading the Early development of Bayer’s Immuno-Oncology portfolio and was subsequently promoted to his current role in 2019. Prior to Bayer, Dr. Raftopoulos led the study teams responsible for the execution and approval of the pivotal chemotherapy-pembrolizumab combination studies in lung cancer at Merck (MSD).
He received his medical degree (MBBCh) from the University of Witwatersrand Medical School in South Africa and completed fellowship and residency at Columbia University Medical Center in New York. As an attending physician at Columbia and later at Northwell, he focused on innovation for patients with lung cancers, leading studies both on research in new agents and on supportive care. During his industry career, he has continued his emphasis on science with patient centricity heading teams that led to approvals for pembrolizumab, larotrectinib and darolutamide. He is an author/ co-author on over 30 papers and review articles.